To address this critical issue, a cell line-specific ODE model for ER+ and PI3K inhibitor-resistant breast cancer was developed to identify potential therapeutic drug combinations to increase drug sensitivity and overcome drug resistance (Gómez Tejeda Zañudo et al. 2021). The gene discussed is ESR1; the disease is breast cancer.